The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.3% since our last review. Ethical screening: PASS with ethical pass with moderate score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (31 analysts) rates it hold, with a mean price target of $337.
Bharat Petroleum
BPCL.NS · NSE · INR · Market cap $1.23T
PASS · Titan Ethical · score 0.0Price as of 13 Nov 2026Daily close, not a live quoteLast reviewed 4 days ago
Screened 2026-11-13 · the tape above runs as of 04:19 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price306.65 INR at the 13 Nov 2026 close
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenPasses, score 0.0 out of 100
- Last reviewed13 Nov 2026 (4 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: range not available (screen dated 2026-11-13).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical passes the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Bharat Petroleum holds its Markup at $306.65. The statistical read favours the buyers, held for 90 days.
| Phase | Markup |
| Quantitative state | The statistical read favours the buyers, held for 90 days |
| Price at the screen | $306.65 |
| Valuation | 0.00 trailing · 0.00 forward price to earnings |
| Values screen | PASS · score 0.0 |
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 21.89% | Below 33% | Interest-bearing debt is just 21.9% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 1.35% | Below 33% | Cash held in interest-bearing accounts and securities is 1.4% of assets, under the one-third limit. | Pass |
| Receivables | 2.13% | Below 49% | Money owed to the company is 2.1% of assets, under the 49% limit. | Pass |
| Revenue purity | 0.41% | Below 5% | Only 0.4% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Clears, in Plain English
Bharat Petroleum clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 22%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-11-15. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when BPCL.NS's ethical verdict changes
Today BPCL.NS passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
| Forward P/E | 0.0x |
| Trailing P/E | 0.0x |
| Revenue growth | +0.0%revenue is shrinking |
| Profit margin | 0.1%barely profitable |
| Dividend yield | 6.77% |
| Market cap | $1.23T |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeBPCL.NS trades on NSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.0% since our last review. Ethical screening: PASS with ethical pass with moderate score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (31 analysts) rates it hold, with a mean price target of $337.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 2.1% since our last review. Ethical screening: PASS with ethical pass with moderate score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (31 analysts) rates it hold, with a mean price target of $337.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 8.3% since our last review. Ethical screening: PASS with ethical pass with moderate score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (31 analysts) rates it hold, with a mean price target of $337.
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 10.1% since our last review. Ethical screening: PASS with ethical pass with moderate score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (31 analysts) rates it hold, with a mean price target of $337.
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical pass with moderate score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (31 analysts) rates it hold, with a mean price target of $337.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (31 analysts) rates it hold, with a mean price target of $337.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (31 analysts) rates it hold, with a mean price target of $337.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. It reported earnings in this window, a natural checkpoint for the thesis.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-11-18 | Life Insurance Corporation of India | Institution- Corporation | 97,057,195 | · |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
This entry now belongs to the ledger. Whatever BPCL.NS does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.